Related Experiment Video
Updated: Jun 29, 2026
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018
Analysis of the coding transcriptome in NSCLC highlights variant-specific gene expression and signaling in CD74-ROS1
Jasmine Vargas1, Julia Olivieri2, Georgios Pantouris3
1Department of Chemistry, University of the Pacific, Stockton, CA, 95211, USA.
Abstract:
The CD74-ROS1 fusion protein is an aggressive oncogenic driver detected in non-small cell lung cancer (NSCLC) patients from stages I-IV. Despite its rare occurrence, CD74-ROS1 has a notable clinical value, with ROS1 inhibitors used as first-line therapeutics in precision medicine. Upon targeting the cancer with ROS1 tyrosine kinase inhibitors (TKIs), resistance occasionally emerges for reasons that are not well-understood. Therefore, analyzing the individual roles of CD74 and ROS1 in the context of the CD74-ROS1 fusion may reveal mechanistic insights that would guide the scientific community to more effective therapies. Here, we describe the development and characterization of A549-transfected CD74-ROS1K439M and CD74∆2-41-ROS1 variants, which together with wild-type CD74-ROS1 and control cells, enable interrogation of each protein partner. Expression analysis of 23,342 genes demonstrates distinct profiles among the variants, with 62 genes identified as differentially expressed between the control and CD74-ROS1 transfected cells. Further analysis designates 13 and 5 of these genes with expression patterns that were influenced by either truncation of the CD74 intracellular domain or the kinase inactivation mutant, respectively. From the genes specified, IL-6 stands out because of its well-established role in NSCLC and its association with CD74. In alignment with the mRNA findings, the phospho-kinase array results expose variant-mediated signaling events that were not previously linked with the functionality of CD74-ROS1. Taken altogether, this study provides an innovative view of CD74 as a fusion partner in CD74-ROS1 and contributes a list of novel molecular targets for mechanistic analysis and drug development.
Insights
Investigating the CD74-ROS1 fusion in non-small cell lung cancer reveals distinct gene expression profiles and signaling events. This research identifies novel molecular targets for developing more effective therapies against this aggressive cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The CD74-ROS1 fusion protein drives aggressive non-small cell lung cancer (NSCLC) and is a target for ROS1 tyrosine kinase inhibitors (TKIs).
- Resistance to TKIs can emerge, necessitating a deeper understanding of the CD74-ROS1 fusion's mechanisms.
- The individual roles of CD74 and ROS1 within the fusion are not fully elucidated.
Purpose of the Study:
- To analyze the distinct roles of CD74 and ROS1 in the CD74-ROS1 fusion.
- To identify novel molecular targets for improved NSCLC therapies.
- To investigate variant-mediated signaling events in CD74-ROS1 functionality.
Main Methods:
- Development and characterization of A549-transfected CD74-ROS1 variants (wild-type, K439M mutant, CD74 intracellular domain truncation).
- Comprehensive gene expression analysis (23,342 genes) comparing variants and control cells.
- Phospho-kinase array analysis to identify variant-mediated signaling pathways.
Main Results:
- Distinct gene expression profiles were observed among the CD74-ROS1 variants.
- 62 genes were differentially expressed between control and CD74-ROS1 transfected cells.
- IL-6 was identified as a key gene influenced by CD74 truncation and kinase mutation, with variant-mediated signaling events revealed by phospho-kinase arrays.
Conclusions:
- CD74 plays a significant role as a fusion partner in CD74-ROS1.
- The study provides a list of novel molecular targets for further mechanistic analysis.
- Findings offer insights for developing more effective therapies against CD74-ROS1 driven NSCLC.
